Gland Pharma Limited (GLAND)
Press Release
Press Release - Q1FY27
- Revenue 18bn +20% y-y; Adj. EBITDA 5.1bn +37% y-y; PAT 3.17bn +47% y-y
- CDMO business grew 20% y-y, contributing 50% of revenues
- B2B business grew 19% y-y, contributing 50% of revenues
- R&D expenses at ₹772 million (4% of revenue), focused on complex product development
- Launched 4 molecules in the USA; 3 ANDAs filed, 7 approved in Q1FY27
- 15 products in co-development, commercialization expected FY28
- Strategic partnerships and capacity expansions support long-term growth
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 GLAND — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add GLAND to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Gland Pharma Limited
Important.
The summary above is generated automatically from Gland Pharma Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.